AU2018333272B2 - Method for treating allergic airways disease (AAD)/ asthma - Google Patents

Method for treating allergic airways disease (AAD)/ asthma Download PDF

Info

Publication number
AU2018333272B2
AU2018333272B2 AU2018333272A AU2018333272A AU2018333272B2 AU 2018333272 B2 AU2018333272 B2 AU 2018333272B2 AU 2018333272 A AU2018333272 A AU 2018333272A AU 2018333272 A AU2018333272 A AU 2018333272A AU 2018333272 B2 AU2018333272 B2 AU 2018333272B2
Authority
AU
Australia
Prior art keywords
mca
mscs
subject
administered
asthma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018333272A
Other languages
English (en)
Other versions
AU2018333272A1 (en
Inventor
Simon ROYCE
Chrishan SAMUEL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cynata Therapeutics Ltd
Original Assignee
Cynata Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2017903758A external-priority patent/AU2017903758A0/en
Application filed by Cynata Therapeutics Ltd filed Critical Cynata Therapeutics Ltd
Publication of AU2018333272A1 publication Critical patent/AU2018333272A1/en
Application granted granted Critical
Publication of AU2018333272B2 publication Critical patent/AU2018333272B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0668—Mesenchymal stem cells from other natural sources
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/069—Vascular Endothelial cells
    • C12N5/0692—Stem cells; Progenitor cells; Precursor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/12—Light metals, i.e. alkali, alkaline earth, Be, Al, Mg
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/03—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from non-embryonic pluripotent stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2511/00—Cells for large scale production

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2018333272A 2017-09-15 2018-08-31 Method for treating allergic airways disease (AAD)/ asthma Active AU2018333272B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2017903758 2017-09-15
AU2017903758A AU2017903758A0 (en) 2017-09-15 Method
PCT/AU2018/050937 WO2019051536A1 (en) 2017-09-15 2018-08-31 METHOD OF TREATING ALLERGIC RESPIRATORY TRACT DISEASE (DAA) / ASTHMA

Publications (2)

Publication Number Publication Date
AU2018333272A1 AU2018333272A1 (en) 2020-03-05
AU2018333272B2 true AU2018333272B2 (en) 2022-12-08

Family

ID=65722228

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018333272A Active AU2018333272B2 (en) 2017-09-15 2018-08-31 Method for treating allergic airways disease (AAD)/ asthma

Country Status (14)

Country Link
US (1) US11471493B2 (enExample)
EP (1) EP3681519B1 (enExample)
JP (1) JP2020533373A (enExample)
KR (1) KR20200053501A (enExample)
CN (1) CN111093680A (enExample)
AR (1) AR112802A1 (enExample)
AU (1) AU2018333272B2 (enExample)
BR (1) BR112020004856A2 (enExample)
CA (1) CA3074470C (enExample)
ES (1) ES2996339T3 (enExample)
MX (1) MX2020002760A (enExample)
SG (1) SG11202001909TA (enExample)
TW (1) TWI806896B (enExample)
WO (1) WO2019051536A1 (enExample)

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100785969B1 (ko) * 2004-05-12 2007-12-14 동아제약주식회사 Ｆｇｆ2를 유효성분으로 포함하는 천식 및 만성폐쇄성폐질환 예방 또는 치료제
US20120164114A1 (en) * 2010-12-17 2012-06-28 Abbot Stewart Treatment of immune-related diseases and disorders using amnion derived adherent cells
EP2823037A4 (en) * 2012-03-07 2015-09-16 Janssen Biotech Inc DEFINED MEDIA FOR THE EXPANSION AND CARE OF PLURIPOTENTAL STEM CELLS
US20150064141A1 (en) * 2012-04-05 2015-03-05 The Regents Of The University Of California Regenerative sera cells and mesenchymal stem cells
JP2015518485A (ja) * 2012-04-20 2015-07-02 アプタミアール セラピューティクス インコーポレイテッド 熱発生のｍｉＲＮＡ調節剤
WO2014011407A2 (en) * 2012-07-12 2014-01-16 Imstem Biotechnology, Inc. Mesenchymal-like stem cells derived from human embryonic stem cells, methods and uses thereof
US10046010B2 (en) * 2012-08-06 2018-08-14 Brainstorm Cell Therapeutics Ltd. Methods of generating mesenchymal stem cells which secrete neurotrophic factors
ES2759281T3 (es) * 2012-12-12 2020-05-08 Mesoblast Inc Métodos de tratamiento o prevención de afecciones respiratorias
PT2970912T (pt) 2013-03-13 2019-05-31 Wisconsin Alumni Res Found Métodos e materiais para a diferenciação hematoendotelial de células estaminais pluripotentes humanas em condições definidas
AU2015367275B2 (en) * 2014-12-19 2021-11-18 Cell Ideas Pty Ltd Improved cell therapies
RU2756561C2 (ru) * 2016-03-16 2021-10-01 Сината Терапьютикс Лимитед Среда для формирования колоний и её применение
EP3493821A4 (en) * 2016-08-04 2020-04-08 Hudson Institute of Medical Research METHOD OF TREATING THE RESPIRATORY TRACT
JP2020523400A (ja) 2017-06-16 2020-08-06 サイナータ セラピューティクス リミテッド 免疫療法の副作用を治療するための方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ROYCE SIMON G., RELE SIDDHARTH, BROUGHTON BRAD R. S., KELLY KILIAN, SAMUEL CHRISHAN S.: "Intranasal administration of mesenchymoangioblast‐derived mesenchymal stem cells abrogates airway fibrosis and airway hyperresponsiveness associated with chronic allergic airways disease", THE FASEB JOURNAL, FEDERATION OF AMERICAN SOCIETIES FOR EXPERIMENTAL BIOLOGY, US, vol. 31, no. 9, 19 September 2017 (2017-09-19), US, pages 4168 - 4178, XP055786138, ISSN: 0892-6638, DOI: 10.1096/fj.201700178R *

Also Published As

Publication number Publication date
TW201919666A (zh) 2019-06-01
US11471493B2 (en) 2022-10-18
MX2020002760A (es) 2020-07-20
ES2996339T3 (en) 2025-02-12
JP2020533373A (ja) 2020-11-19
WO2019051536A1 (en) 2019-03-21
BR112020004856A2 (pt) 2020-09-15
RU2020111190A (ru) 2021-10-15
CN111093680A (zh) 2020-05-01
EP3681519A4 (en) 2021-04-28
KR20200053501A (ko) 2020-05-18
TWI806896B (zh) 2023-07-01
RU2020111190A3 (enExample) 2022-03-30
US20200276243A1 (en) 2020-09-03
CA3074470A1 (en) 2019-03-21
AR112802A1 (es) 2019-12-11
SG11202001909TA (en) 2020-04-29
EP3681519A1 (en) 2020-07-22
CA3074470C (en) 2024-01-16
EP3681519B1 (en) 2024-10-30
AU2018333272A1 (en) 2020-03-05
EP3681519C0 (en) 2024-10-30

Similar Documents

Publication Publication Date Title
US20220090008A1 (en) Colony forming medium and use thereof
AU2020244403B2 (en) Treatment of immune disorders
JP2020075935A (ja) 幹細胞の免疫制御作用を調節する方法
CN104204193A (zh) 间充质干细胞的培养
US20110044958A1 (en) Activated mesenchymal stem cells for the prevention and repair of inflammatory states
Ikhapoh et al. Sry-type HMG box 18 contributes to the differentiation of bone marrow-derived mesenchymal stem cells to endothelial cells
US20170136065A1 (en) Mesenchymal stromal cells for treating rheumatoid arthritis
AU2018333272B2 (en) Method for treating allergic airways disease (AAD)/ asthma
RU2790031C2 (ru) Способ лечения аллергического заболевания дыхательных путей (AAD)/астмы
HK40024451B (en) Method for treating allergic airways disease (aad)/ asthma
HK40024451A (en) Method for treating allergic airways disease (aad)/ asthma
CN106659560A (zh) 生殖腺来源的侧群干细胞
EP3873503B1 (en) Treatment of cachexia using fibroblast cells and products thereof
WO2022241090A9 (en) Methods and compositions for treating liver disease
HK40000643A (en) Colony forming medium and use thereof
HK40000643B (en) Colony forming medium and use thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)